Online inquiry

IVTScrip™ pSP6-VEE-mRNA-Anti-PDGFRA, 3G3 Vector   (CAT#: GTVCR-WQ86MR)

This product GTVCR-WQ86MR is an effective transcription system suitable for a variety of research, including the in vitro translation, self-amplifying mRNA studies and protein expression. The system was driven by the SP6 promoter to efficiently generate mRNA ecoding antibody which targeting PDGFRA. The vector contains the self-replicating Venezuelan equine encephalitis (VEE) virus RNA replicon, which resulting the mRNA expression at a high level.

SPECIFIC INQUIRY

3' poly(A):
Inquiry
Specifications
Product type Vector
Promoter SP6
Resistance Ampicillin
Species Homo sapiens
RefSeq NM_001347829.2
Applications IVT; Self-amplifying mRNA (SAM) research; Gene therapy research
Format Solution
Concentration 1 µg/µl
Quantity 10 µg
Target Gene
Gene ID 5156
UniProt ID P16234
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ pSP6-VEE-mRNA-Anti-PDGFRA, 3G3 Vector (GTVCR-WQ86MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTVCR-WQ1659MR IVTScrip™ pT7-VEE-mRNA-Anti-CSF2, KB-003 Vector Vector KB-003
GTVCR-WQ218MR IVTScrip™ pSP6-VEE-mRNA-Anti-DLL4&VEGFA, ABT-165 Vector Vector ABT-165
GTVCR-WQ1734MR IVTScrip™ pSP6-VEE-mRNA-Anti-IL17A&TNFSF13B, LY 3090106 Vector Vector LY 3090106
GTVCR-WQ2008MR IVTScrip™ pT7-VEE-mRNA-Anti-ERBB3, MM-121 Vector Vector MM-121
GTVCR-WQ1459MR IVTScrip™ pT7-VEE-mRNA-Anti-F3, HuMax-TF-ADC Vector Vector HuMax-TF-ADC
GTVCR-WQ1094MR IVTScrip™ pSP6-VEE-mRNA-Anti-CD274, CX-072 Vector Vector CX-072
GTVCR-WQ2479MR IVTScrip™ pT7-VEE-mRNA-Anti-CD70, SGN-75 Vector Vector SGN-75
GTVCR-WQ727MR IVTScrip™ pT7-VEE-mRNA-Anti-C1S, BIVV009 Vector Vector BIVV009
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW